INTRODUCTION {#s1}
============

High-throughput sequencing (HTS) technologies have dramatically accelerated the pace of human disease genetics ([@MCS005306KOBC20]). Exome and genome sequencing have elucidated the genetic basis for thousands of rare inherited disorders in the past decade. HTS has also supplanted other genomic interrogation technologies for the vast majority of clinical genetic tests; for patients with rare disorders of likely genetic etiology, clinical exome sequencing is often a frontline diagnostic test. Despite this progress, a recent meta-analysis of 37 studies comprising 20,068 children found that the diagnostic utility of exome sequencing (ES) and whole-genome sequencing (WGS) is only 36%--41% ([@MCS005306KOBC5]). That proportion has changed little despite the continued identification of novel disease genes. It is likely that an appreciable number of undiagnosed cases harbor pathogenic variants in known disease genes that are refractory to identification by current clinical genetic testing paradigms. Patients who are clinically diagnosed with a disease of well-established etiology but whose clinical genetic test results are negative offer an opportunity to characterize these "occult" pathogenic variants using new genomic and analytic techniques.

Wilson disease (WD) is a rare recessive disorder characterized by a dramatic accumulation of intracellular copper---primarily in the liver and brain---as a result of defective copper excretion ([@MCS005306KOBC7]). It was first described more than a century ago by neurologist S.A. Kinnier Wilson, who called it *progressive lenticular degeneration*, a "familial nervous system disease" involving cirrhosis of the liver (Wilson 1912; [@MCS005306KOBC2]). Clinical manifestations include not only hepatic abnormalities (e.g., cirrhosis) but also neurologic and psychiatric symptoms. Clinical diagnosis is often possible before the appearance of neurologic symptoms through biochemical testing for reduced serum ceruloplasmin (assay-dependent cutoff generally \<20 mg/dL) and elevated 24-h urinary copper (\>40 mcg) ([@MCS005306KOBC28]). The worldwide incidence of WD is estimated at 1:30,000 to 1:100,000, although incidence as high as 1:7000 has been reported in founder populations ([@MCS005306KOBC24]).

WD is caused by biallelic variants in the *ATP7B* gene at Chr 13q14.3 ([@MCS005306KOBC3]; [@MCS005306KOBC26]; [@MCS005306KOBC30]). This gene encodes a metal-transporting P-type adenosine triphosphatase (ATPase) whose function is in the transmembrane transport of copper within hepatocytes, ultimately shuttling copper for excretion into the bile. Absence, reduction, or decreased function of the ATP7B protein leads to hepatic copper accumulation and injury ([@MCS005306KOBC28]; [@MCS005306KOBC2]). *ATP7B* is highly homologous with *ATP7A*, an X-linked gene in which mutations cause Menkes disease, an essentially inverse phenotype of generalized copper deficiency ([@MCS005306KOBC13]). Both *ATP7B* and *ATP7A* encode evolutionarily conserved transmembrane proteins with metal-binding and ATPase domains ([@MCS005306KOBC7]; [@MCS005306KOBC27]). Some 192 variants in *ATP7B* have been reported as pathogenic or likely pathogenic to the ClinVar database; of these, loss-of-function variants including frameshift (*n* = 72), nonsense (*n* = 35), and splice site (*n* = 29) variants together represent \>70% of disease-causing alterations. More than 500 disease-causing variants in *ATP7B* were reported to the Wilson Disease Mutation Database (2001--2010) ([@MCS005306KOBC18]). Although more than half such variants are missense changes, appreciable proportions of loss-of-function variants (nonsense, frameshift, and splice site) were reported.

The clinical testing method to identify *ATP7B* variants uses a combination of next-generation sequencing (NGS) and Sanger sequencing technologies to cover the full coding regions of *ATP7B* plus ∼10 bases on noncoding DNA flanking each exon. Copy-number variants of four exons or more in size are detected through analysis of NGS data with sensitivity approaching 100%. The clinical sensitivity of this approach is listed as ∼98% among individuals with WD (Prevention Genetics; <https://www.preventiongenetics.com/testInfo?val=Wilson+Disease+%2F+Hepatolenticular+Degeneration+via+the+ATP7B+Gene>).

We report a proband from a consanguineous family who carried a clinical and biochemical diagnosis of WD but whose clinical molecular genetic testing was negative. Through a combination of WGS, RNA sequencing, and computational analysis, we determined that the disease is caused by exon skipping in *ATP7B* associated with a novel intronic variant. Our analysis also revealed that the proband\'s 7-yr-old younger sister, who was clinically asymptomatic, was homozygous for this variant. Her subsequent clinical workup revealed biochemical evidence of WD consistent with the molecular genetic findings. Our work adds to emerging evidence that exon skipping in *ATP7B* represents a common etiology for WD and illustrates the value of applying new genomic interrogation techniques to identify occult pathogenic variants.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

The proband is an 8-yr-old Palestinian male who presented to the Nationwide Children\'s Hospital Gastroenterology Clinic shortly after he and his father came to the United States. The family was evaluated with an Arabic interpreter (pedigree in [Fig. 1](#MCS005306KOBF1){ref-type="fig"}A). The proband had been diagnosed with WD by a physician in Jordan at 5 yr of age. He reportedly was receiving oral penicillamine at the time of his initial examination in the United States. The family noted that the diagnosis of WD had been established based on pallor, hepatomegaly, and findings on eye exam (presumed to be Kayser--Fleischer rings). We were unable to contact the clinician who made the original clinical diagnosis and the patient presented without pertinent clinical records.

![Clinical and family history. (*A*) Family pedigree with disease status (shading) and genotypes for the c.1947-19A \> T variant, if known. The proband is indicated with an arrow. (*B*) Biochemical test results for three children who were tested. (ALT) Alanine transaminase, (AST) aspartate transaminase, (ND) not done.](MCS005306Kob_F1){#MCS005306KOBF1}

Evaluations for the proband at our hospital included an abdominal ultrasound that showed severe hepatomegaly with steatosis and mild splenomegaly. On laboratory evaluation ([Fig. 1](#MCS005306KOBF1){ref-type="fig"}B), serum transaminases were mildly elevated (ALT 209/AST 112) and serum ceruloplasmin was undetectable. The 24-h urine copper was markedly elevated (409.6). Repeat eye exam noted right conjunctival nevus but detected no Kayser--Fleischer rings. However, the proband was diagnosed at a relatively young age and started chelation therapy in his home country, which may explain the absence of corneal copper deposits. A liver needle biopsy showed marked panlobular steatosis, with moderate necroinflammatory activity present, ballooning cell injury and cirrhosis, and elevated copper (1448 mcg/g; normal ≤35 mcg/g).

Commercial *ATP7B* sequencing with copy-number variant (CNV) detection performed by Prevention Genetics (test code 7871) reported no sequence variants likely to be a primary cause of disease. Single-nucleotide polymorphism (SNP) chromosomal microarray was consistent with ∼8.96% homozygosity across the autosomal genome. A run of homozygosity (ROH) within the 13q14.3q31.3 region encompassing *ATP7B* was noted. A family pedigree showed three younger full siblings whose disease status was unknown. Two siblings reside in the United States; the third resides overseas and was unavailable for testing.

Genomic Analyses {#s2b}
----------------

Given the clinical diagnosis of Wilson disease and ROH at Chr 13q14.3 noted from array testing, we suspected that an occult variant in *ATP7B* was the likely cause of disease. We therefore elected to perform WGS on peripheral blood from proband (II.1) and available family members (both parents, I.1 and I.2, and his younger sister, II.2; [Fig. 1](#MCS005306KOBF1){ref-type="fig"}A). At the time, the sister (II.2) was presumed healthy and had not undergone extensive clinical evaluations. We also performed RNA-seq on frozen liver tissue from the proband, which had been obtained as part of the clinical workup, and requested the raw sequence data for the *ATP7B* clinical testing from Prevention Genetics.

Genome Sequencing {#s2c}
-----------------

We performed WGS on the four family members on an Illumina NovaSeq6000 instrument (2 × 150 bp), generating ∼162 Gbp per sample on average. Mapping the sequence reads to the GRCh37 reference sequence yielded ∼45.4× haploid coverage per sample (range 43.1× to 47.5×; see [Table 1](#MCS005306KOBTB1){ref-type="table"} for metrics).

###### 

Sequencing metrics

                                    Proband   Mother   Father   Sibling
  --------------------------------- --------- -------- -------- ---------
  RNA sequencing (liver)                                        
   Total reads (millions)           250.6                       
   Unmapped                         3.31%                       
   HQ mapped                        88.27%                      
   LQ mapped                        7.31%                       
   Ribosomal mapped                 1.12%                       
   Coding/UTR reads (millions)      138.4                       
   Coding/UTR fraction              62.56%                      
  Whole-genome sequencing (blood)                               
   Total sequence (Gbp)             168       159      156      164
   Mean read length (bp)            145.2     145.2    145.2    145.1
   Map rate (b37)                   97.86%    97.97%   96.96%   97.87%
   Duplication rate                 6.61%     7.04%    6.47%    6.59%
   Median insert size (bp)          340       346      326      341
   Average depth                    47.5×     45.1×    43.1×    45.7×

(Top) RNA sequencing metrics for proband liver tissue obtained via biopsy for clinical purposes. (Bottom) Whole-genome sequencing metrics for genomic DNA from peripheral blood. All samples were sequenced on Illumina NovaSeq instruments (2 × 150 bp).

(HQ) High quality (mapping quality \> 0), (LQ) low quality (mapping quality = 0), (UTR) untranslated region.

Genome and Variant Analysis {#s2d}
---------------------------

Consistent with previous testing, our analysis of WGS data for the proband revealed ROH encompassing ∼9.73% of the genome, including a ∼3.93-Mbp segment at Chr 13q14.3-q31.3 ([Fig. 2](#MCS005306KOBF2){ref-type="fig"}A) that covers the *ATP7B* locus. Multisample variant calling in the family quad uncovered 155 small variants (SNVs/indels) that were annotated in or near *ATP7B* by the Variant Effect Predictor (VEP 90). Of these, the vast majority (*n* = 127) had a minor allele frequency of \>0.05 in the gnomAD database ([@MCS005306KOBC22]), making them too common to cause a recessive disorder. Another five variants were manually reviewed by trained reviewers using the Integrative Genomics Viewer and were deemed to represent local alignment artifacts (misalignment of reads to the reference sequence) rather than true variation. The 23 variants passing these filters are detailed in [Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a005306/-/DC1). Of these, 20 had global minor allele frequency (MAF) \> 0.01 and at least two homozygotes in the gnomAD database and are thus unlikely to cause disease. One variant was a small homopolymer insertion in a low-complexity repeat region, and one variant with somewhat low MAF (rs558801757, MAF = 0.0041) is located more than 1700 bp downstream from the ATP7B region and thus deemed unlikely to affect splicing.

![Genomic analysis of case RD190073. (*A*) Run of homozygosity (ROH) analysis using VarScan v2.3.4 reveals a large ROH region on Chromosome 13 overlapping the *ATP7B* gene, indicated by a red arrow. (*B*) Integrative Genomics Viewer (IGV) screenshot of proband genome sequence (*top* track) and transcriptome sequence (*bottom* track). Exons 6 and 7 are not expressed in the RNA (red arrows). (*C*) IGV screenshot of the c.1947-19T \> A variant showing its proximity to the exon and zygosity (homozygous in the proband, heterozygous in both parents).](MCS005306Kob_F2){#MCS005306KOBF2}

The remaining variant was an A-to-T change in the sixth intron of *ATP7B* (NM_000053.4:c.1947-19T \> A). It is not present in the gnomAD database (120,839 individuals had coverage). This suggests that the variant is extremely rare, although it should be noted that Middle Eastern populations are underrepresented in public sequence databases. Of note, this variant is close enough to the nearby exon that it achieved good coverage and was clearly visible in the panel sequencing data (184× depth). However, it was not reported by the testing provider, likely because it lies well beyond the canonical splice site and does not appear to be conserved (Genomic Evolutionary Rate Profiling-rejected substitutions \[GERP-RS\] score = −0.68, DANN score = 0.8337).

RNA Sequencing Reveals Exon 6--7 Skipping {#s2e}
-----------------------------------------

We next examined expression data from the proband\'s liver tissue. As expected, *ATP7B* is highly expressed in liver tissue; we achieved ∼200×--300× read depth across most of the gene. However, read depth was \<35× in exons 6 and 7 despite 250×--300× depth at the adjacent exons (5 and 8), suggesting absence of these exons in processed transcripts ([Fig. 2](#MCS005306KOBF2){ref-type="fig"}B, bottom track). In support of this, at least 22 exon-spanning reads (blue arcs) map from exon 5 to exon 8, with no sequence aligning to exons 6 and 7. There were 13 RNA-seq reads present at the intronic position c.1947-19T \> A, likely reflecting unprocessed mRNA transcripts. All 13 contained the variant allele, which offers independent molecular confirmation that the variant is real and not a sequencing or alignment artifact.

Because the c.1947-19T \> A variant was the only plausible genomic source of the splice disruption, we analyzed the variant and its sequence context in detail with two independent tools, Human Splicing Finder (HSF) v3.1 ([@MCS005306KOBC8]) and RBPmap v1.1 ([@MCS005306KOBC25]). Using the reference or variant allele with ±30 bp of flanking sequence in each direction, we identified two factors that showed strikingly different results between reference and variant alleles ([Table 2](#MCS005306KOBTB2){ref-type="table"}). First, we found that the variant allele disrupts a predicted binding motif of SC35 (SRSF2), a splice enhancer, reducing its HSF score from 77.01 to 61.89 (below the default threshold of 75.05). Similarly, RBPmap predicts a high-scoring SC35 motif for the reference allele (*Z* = 2.495, *P* = 0.0063) but a low-stringency match (*Z* = 1.949, *P* = 0.0256) for the variant allele. Second, we found that the variant allele creates a high-scoring motif for heterogeneous nuclear ribonucleoprotein (hnRNP) A1, a splicing silencer (HSF score = 70.24, threshold = 65.476). RBPmap supports these results, predicting a high-scoring hnRNP A1 motif for the variant allele (*Z* = 2.623, *P* = 0.00436) but no matching motif for the reference allele. These computational results predict that the c.1947-19T \> A variant disrupts a splice enhancer while creating a splicing silencer motif, results consistent with the aberrant splicing pattern we observed. The variant\'s position between the two affected exons and the lack of any other viable candidate variants in the region offer compelling evidence that the c.1947-19T \> A variant is the cause of the aberrant splicing.

###### 

Results of splice motif analysis for variant position ±30 bp

  Position   Motif            Factor         HSF Ref Score   HSF Alt Score   RBP Ref *Z*-score   RBP Alt *Z*-score
  ---------- ---------------- -------------- --------------- --------------- ------------------- -------------------
  −22        TGT\[T/A\]GCTG   SC35 (SRSF2)   77.01           61.89\*         2.495               1.949\*
  −20        T\[T/A\]GCTG     hnRNP A1       34.52\*         70.24           n/a\*               2.623

Shown are the scores for two factors whose motifs are affected using either the reference (Ref) or alternate (Alt) allele from Human Splicing Finder (HSF) and RBPmap (RBP). Scores marked with (\*) are below the default threshold for the factor.

(hnRNP) Heterogeneous nuclear ribonucleoprotein.

Impact of Exon 6--7 Loss {#s2f}
------------------------

Exon 6 (77 bp) and exon 7 (175 bp) are normally expressed in ATP7B in liver tissue, and together encode precisely 84 amino acids (residues 624--707) of the protein ([Fig. 3](#MCS005306KOBF3){ref-type="fig"}A). By analogy to *ATP7A*, exon 6 of *ATP7B* encodes a short cytosolic segment linking the molecule\'s copper-binding region (six recurring CXXC motifs) to the initial transmembrane (TM) segment ([@MCS005306KOBC15]; [@MCS005306KOBC14]). Exon 7 is predicted to encode the first two transmembrane helices attached by a luminal loop. Although deletion of these exons would not disrupt the proper *ATP7B* translational reading frame, it would severely impair the mutant protein\'s copper transport capacity. The first two transmembrane segments normally enable formation of a copper "platform" as determined by X-ray crystallography of the homologous *Legionella pneumophila* CopA copper ATPase ([@MCS005306KOBC12]). This crystal structure indicates a three-stage copper transport pathway involving several conserved residues including a transmembrane kink at a double-glycine motif displaying an amphipathic helix lining a putative copper entry point. The double glycine link is specific for P-type ATPases of the class IB including ATP7A ([@MCS005306KOBC33]) and occurs in exon 8 of *ATP7B*, within two residues of the exon 7 boundary. In the absence of exons 6 and 7, this double-glycine motif would mislocalize to the cytosolic aspect of intracellular compartments, impeding proper transmembrane copper passage. Analogous exon skipping has been reported in classic Menkes disease patients with an *ATP7A* splice junction variant that generated multiple mutant transcripts, none of which appeared functional ([@MCS005306KOBC15]).

![Impact of aberrant splicing on ATP7B structure. (*A*) Exon structure of ATP7B, with even and odd numbered exons differently colored for distinction. (*B*) Protein structure of ATP7B showing key structural elements and functional domains. Region boundaries were obtained from PFAM (Cu-binding domains) or the published crystal structure of ATP7B (all others). Skipping of exons 6 and 7 (dotted rectangle) removes 84 amino acids (residues 624--707), removes the first transmembrane domain (often called TMA), and may also impact the sixth Cu-binding domain (MBD6) and second transmembrane domain (TMB).](MCS005306Kob_F3){#MCS005306KOBF3}

Evaluation of Family Members {#s2g}
----------------------------

Although the proband\'s 7-yr-old sister was described as healthy at the time of enrollment, genome sequencing revealed that she, too, had a large ROH encompassing the *ATP7B* gene region ([Supplemental Fig. 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a005306/-/DC1)) and was homozygous for the c.1947-19T \> A variant ([Table 3](#MCS005306KOBTB3){ref-type="table"}). Based on this finding, she underwent clinical evaluation at our hospital. She had elevated transaminases (ALT 173 U/l, AST 373 U/l), low serum ceruloplasmin, and high urinary copper excretion ([Fig. 1](#MCS005306KOBF1){ref-type="fig"}B). She had normal albumin (4.8 g/dL), alkaline phosphatase (278 U/L), and bilirubin (0.6 mg/dL). Complete blood count (CBC) showed normal values for white blood cells (WBCs) 6.0 × 10^3^/µL, hemoglobin (Hgb) 13.7 g/dL, hematocrit (Hct) 39.2%, and platelet count (Plt) 362 × 103/µL. International normalized ratio (INR) and prothrombin time (PT) were not elevated at 0.97 and 12.9 sec, respectively. Her liver copper was elevated (1128 mcg/g; normal ≤ 35 mcg/g), confirming a diagnosis of Wilson disease. Thus, our genomic analysis enabled early diagnosis of a second family member.

###### 

Genomic findings and variant interpretation

  Gene      Variant                       HGVS                           Proband   Mother   Father   Sibling  Interpretation
  --------- ----------------------------- ----------------------------- --------- -------- -------- --------- -------------------------
  *ATP7B*   Chr 13: 52534477 A/T (hg19)   NM_000053.4:c.1947-19T \> A      Hom      Het      Het       Hom    LP (PS3, PM2, PP1, PP4)

Genomic coordinates reflect build GRCh37.

(HGVS) Human Genome Variation Society, (Hom) homogeneous, (Het) heterogeneous, (LP) likely pathogenic.

Variant Interpretation {#s2h}
----------------------

Variant interpretation under American College of Medical Genetics and Genomics (ACMG) recommended guidelines is challenging for this variant. It is absent from public databases (PM2) and segregates with disease in the proband under the expected recessive inheritance pattern (PP1), and the phenotype is specific for a disease with a single known genetic etiology (PP4). This genomic evidence alone is insufficient to make a classification other than variant of uncertain significance (VUS). However, we would argue that the aberrant splicing observed in the proband\'s liver tissue (i.e., skipping of exons 6--7), together with our computational analysis, represents in vivo functional evidence that the variant disrupts the ATP7B gene product. In this view, the PS3 criterion would also apply, which would shift the variant\'s classification to likely pathogenic ([Table 3](#MCS005306KOBTB3){ref-type="table"}).

DISCUSSION {#s3}
==========

WD is a medically actionable autosomal recessive disorder of copper metabolism with variable age of clinical presentation. *ATP7B* is the only gene known to cause WD. The phenotype of WD is clinically distinct from other disorders of copper metabolism such as Menkes disease and MEDNIK syndrome ([@MCS005306KOBC31]). Considering this, as well as the fact that the SNP ROH encompassed the *ATP7B* gene, a hidden variant involving *ATP7B* was suspected. WGS identified a homozygous deep intronic variant that is predicted to cause exon skipping by splicing computational tool. RNA-seq data showed 90% lower expression of exons 6 and 7, which is consistent with exon skipping. Removing amino acids 624--707 of the ATP7B protein would affect metal binding domain (MBD6) which would be expected to disrupt copper transport activity ([@MCS005306KOBC29]). The c.1947-19T \> A is the only plausible genomic variant in this region to underlie the aberrant splicing. Because homozygosity for this variant segregates with WD in the family, further support of disease causality is evident. Analysis of the Δ exon 6--7 *ATP7B* transcript by yeast complementation ([@MCS005306KOBC11]; [@MCS005306KOBC16]) could provide a formal laboratory-based approach to confirm loss of copper transport function, although this was not completed given the multiple other lines of supporting evidence.

Several hundred disease-causing variants in *ATP7B* have been reported to the Wilson Disease Mutation Database ([@MCS005306KOBC18]), the Human Gene Mutation Database, and the ClinVar database. Less than half are classified as unequivocal loss-of-function variants (nonsense, frameshift, or splice site). Canonical splice site variants presumably disrupt splicing and are generally considered pathogenic, but the impact of variants at other positions in the splice region is less certain ([@MCS005306KOBC10]). However, there is emerging evidence that variants outside of the canonical splice site can disrupt ATP7B function via effects on splicing. Wang et al. used a minigene assay to identify both missense and synonymous coding variants that caused exon skipping in *ATP7B* ([@MCS005306KOBC32]). Liu et al. used a similar approach to show that a variant in intron 4 (c.1707 + 5G \> A) causes exon 4 skipping ([@MCS005306KOBC23]). To our knowledge, the c.1947-19T \> A variant in our family is the deepest intronic variant to be implicated in *ATP7B* exon skipping to date.

Clinical recognition of WD can be difficult as there is no single specific clinical or biochemical finding pathognomonic for the diagnosis. In equivocal situations, liver biopsy for copper quantification can be useful but has the drawback of being invasive and may be negative in early stages of WD. Molecular genomic testing is an extremely useful addition to the diagnostic armamentarium; however, as in the case described here, some disease-causing variants may not be detected by standard clinical genetic testing.

METHODS {#s4}
=======

Clinical Workup {#s4a}
---------------

Serum ceruloplasmin levels for the proband and his sibling were measured by nephelometric immunoassay on a Siemens BNII nephelometer. Urine copper was measured by inductively coupled plasma mass spectrometry (ICP-MS). Ophthalmologic evaluation of the proband included a fundus examination and slit-lamp exam. Commercial genetic testing was performed by Prevention Genetics (test code 7871, "ATP7B gene sequencing with CNV detection") using genomic DNA from proband whole blood. According to the report, the test achieved 325× average NGS coverage, with 100% of bases covered (≥20× for exons and ±10 bp of flanking DNA). The report of negative findings was received in February 2019.

Library Preparation {#s4b}
-------------------

Following consent and enrollment, genomic DNA from the proband, parents, and younger sister was extracted from peripheral blood. Paired-end genome sequencing libraries were constructed using NEBNext Ultra II FS DNA Library Prep Kit (New England BioLabs) according to manufacturer protocols. RNA was extracted from a previously frozen liver needle biopsy specimen obtained as part of the proband\'s clinical workup; sequencing libraries were constructed using NEBNext Ultra II RNA Library Prep Kit (New England BioLabs) according to manufacturer protocols.

RNA Sequencing and Analysis {#s4c}
---------------------------

RNA from the liver specimen underwent DNase treatment and ribodepletion prior to library construction using Illumina\'s TruSeq Stranded total RNA kit. RNA sequencing was performed using a NovaSeq6000 instrument (2 × 150 bp) according to manufacturer protocols generating 150.6 million reads. The default RNA-seq pipeline aligned reads to the GRCh37 (hg19) assembly of the human using version 2.6.0c of the RNA-Seq aligner STAR ([@MCS005306KOBC9]). Transcript features were identified from the GFF file provided with the assembly from NCBI and raw coverage counts were calculated using HTSeq ([@MCS005306KOBC1]) v0.10.0.

Genome Sequencing and Analysis {#s4d}
------------------------------

WGS was performed on genomic DNA from the proband, mother, father, and two full siblings (II.2 and II.4) using an Illumina NovaSeq6000 instrument according to manufacturer protocols. Reads were mapped to the GRCh37 reference sequence and secondary data analysis was performed using Churchill ([@MCS005306KOBC17]), which implements the GATK "best practices" workflow for alignment, variant discovery and genotyping. The average sequence depth achieved was ∼45.4× for the blood samples (proband, mother, father, and sibling); detailed sequencing metrics are provided in [Table 1](#MCS005306KOBTB1){ref-type="table"}. Variants were joint-called in all family members using GATK 4.0.5.1, and the resulting VCF file was annotated with gene, transcript, function class, damaging scores, and population allele frequencies using an in-house pipeline built around the SNPeff ([@MCS005306KOBC4]) annotation tool. ROH analysis was performed using VarScan ([@MCS005306KOBC19]) v2.4.3.

Our general approach to variant annotation and prioritization has already been described ([@MCS005306KOBC21]). After removing common variants (MAF \> 0.01 in the gnomAD database), we selected for further analysis all splice site, frameshift, and nonsense variants, as well as missense variants predicted to be damaging by SIFT (score \< 0.05), PolyPhen (score \> 0.453), GERP (score \> 2.0), or CADD (Phred score \> 15). Because of the family history, we prioritized rare variants segregating with disease under a recessive inheritance model (i.e., homozygous in the proband, heterozygous in both parents). Other inheritance models---dominant de novo, compound heterozygous, and X-linked---were considered but did not produce compelling candidate variants in the gene associated with WD.
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